トップページ [regulatory-approved] treatment for LA-PAC in nearly 30 years1,2
For locally advanced pancreatic adenocarcinoma,
Optune Pax® delivers quality survival without adding systemic toxicity
by targeting the electrical vulnerability of cancer cells1
Efficacy proven in the largest phase 3 trial in LA-PAC (N=571)2,3
Skin AEs were observed in 76.3% of patients and the majority were mild to moderate.1,2
An innovative treatment for LA-PAC
Optune Pax is an innovative wearable treatment that delivers alternating electric fields, TTFields, continuously to the tumor site.1,4
Actor portrayal.
Optune Pax uses TTFields to disrupt cancer cell viability without significantly affecting healthy cells1
Seamlessly integrate Optune Pax into your practice
MyNovocure® is here to help with hands-on support and personalized assistance for your practice and your patients who are prescribed Optune Pax.
Actor portrayals.
More about TTFields therapy,
the treatment modality for Optune Pax
the treatment modality for Optune Pax
[35,000+]
patients treated
across indications5
5 [regulatory
approved]
solid
tumor indications1,6-8
- LA-PAC
- mNSCLC
- MPM
- Newly diagnosed GBM
- Recurrent GBM
AE, adverse event; GBM, glioblastoma; gem/nab-pac, gemcitabine plus nab-paclitaxel; LA-PAC, locally advanced pancreatic adenocarcinoma; mNSCLC, metastatic non-small cell lung cancer; mOS, median overall survival; MPM, malignant pleural mesothelioma; TTFields, Tumor Treating Fields; TTPP, time to pain progression.
References: 1. Optune Pax for Locally Advanced Pancreatic Cancer. Physician Instructions for Use. Novocure; 2025. 2. Babiker HM, Picozzi V, Chandana SR, et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase III PANOVA-3 study. J Clin Oncol. 2025;43(21):2350-2360. doi:10.1200/JCO-25-00746 3. Picozzi VJ, Babiker HM, Chandana SR, et al. LBA4005: PANOVA-3: phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC). Accessed October 17, 2025. https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA4005 4. Novocure Data on File GLB-DOF-0035. 5. Novocure Data on File US-DOF-0057. 6. Optune. Instructions for Use. Novocure; 2019. 7. Optune Lua for non-small cell lung cancer (NSCLC). Physician Instructions for Use. Novocure; 2024. 8. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021.